Management of Psoriasis through panchakarma
Phase 2
Not yet recruiting
- Conditions
- Health Condition 1: L99- Other disorders of skin and subcutaneous tissue in diseases classified elsewhere
- Registration Number
- CTRI/2021/10/037687
- Lead Sponsor
- All India Institute of Ayurveda
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
PASI Score: > 10
Moderate to severe
Chronicity: up to10 years
Patients having the clinical features of Psoriasis (Kitibha Kushtha).
Exclusion Criteria
Chronicity of more than 10 years
PASI score <10
Patients with Severe Systemic disorders
Pregnant women and lactating mothers
Patients unfit for Rookshana Snehana, Swedana,Vamana and Virechana Karma
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the anti-inflammatory effects of Vamana and Virechana in psoriasis?
How does panchakarma therapy compare to conventional biologics in modulating Th17 pathways in psoriasis vulgaris?
Which immunological biomarkers are most responsive to Shodhana Karma in psoriatic patients with elevated IL-23 levels?
What adverse events are associated with Ayurvedic Shodhana protocols and how do they compare to methotrexate toxicity profiles?
Are there synergistic effects when combining panchakarma detoxification with TNF-alpha inhibitors for moderate-to-severe plaque psoriasis?